CellaVision AB (publ) (CVLLY)

Market Cap	420.40M -5.6%
Revenue (ttm)	76.26M -1.6%
Net Income	13.32M -14.6%
EPS	0.56 -14.6%
Shares Out	n/a
PE Ratio	31.56
Forward PE	25.86
Dividend	0.07 (1.05%)
Ex-Dividend Date	Apr 30, 2026

Volume	n/a
Open	7.06
Previous Close	7.06
Day's Range	7.06 - 7.06
52-Week Range	6.30 - 9.04
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides analyzers for microscopy systems; and DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and Cella...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1994
• Employees: 251
• Stock Exchange: OTCMKTS
• Ticker Symbol: CVLLY

Financial Performance

In 2025, CellaVision AB's revenue was 758.97 million, an increase of 4.94% compared to the previous year's 723.22 million. Earnings were 153.08 million, an increase of 8.78%.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 25, 2026

Data Sources Report a data error